52 results
DEFR14A
ARAV
Aravive Inc
22 Sep 23
Revised proxy
5:04pm
in the footnotes to this table and subject to community property laws where applicable, we believe that each of the stockholders named in this table has sole
8-K
EX-99.1
hjr5zq1p9ec5x1kz3
5 Jul 22
Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer
7:05am
8-K
ngpqvflbloeiw4abjh
5 Jul 22
Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer
7:05am
424B3
kz0y hj1t2
19 Jan 22
Prospectus supplement
4:05pm
8-K
EX-99.1
oxmzds0kdxlhbin6sx
9 Nov 21
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline
8:29am
8-K
EX-99.1
jif020p
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
424B5
wpb0 mzmmw
16 Feb 21
Prospectus supplement for primary offering
7:05am